MX2012003394A - O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators. - Google Patents
O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators.Info
- Publication number
- MX2012003394A MX2012003394A MX2012003394A MX2012003394A MX2012003394A MX 2012003394 A MX2012003394 A MX 2012003394A MX 2012003394 A MX2012003394 A MX 2012003394A MX 2012003394 A MX2012003394 A MX 2012003394A MX 2012003394 A MX2012003394 A MX 2012003394A
- Authority
- MX
- Mexico
- Prior art keywords
- positive allosteric
- allosteric modulators
- compounds
- nicotinamide analogs
- benzyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
In one aspect, the invention relates to 0-benzyl nicotinamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24441709P | 2009-09-21 | 2009-09-21 | |
PCT/US2010/049697 WO2011035324A1 (en) | 2009-09-21 | 2010-09-21 | O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012003394A true MX2012003394A (en) | 2012-08-15 |
Family
ID=43759065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012003394A MX2012003394A (en) | 2009-09-21 | 2010-09-21 | O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110183980A1 (en) |
EP (1) | EP2482657A4 (en) |
JP (1) | JP2013505297A (en) |
CN (1) | CN102638979A (en) |
AU (1) | AU2010295288A1 (en) |
BR (1) | BR112012006330A2 (en) |
CA (1) | CA2774981A1 (en) |
IL (1) | IL218772A0 (en) |
IN (1) | IN2012DN03322A (en) |
MX (1) | MX2012003394A (en) |
RU (1) | RU2012116124A (en) |
WO (1) | WO2011035324A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011075699A2 (en) | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
JP2013526610A (en) * | 2010-05-24 | 2013-06-24 | ヴァンダービルト ユニバーシティー | Substituted 6-methylnicotinamide as a positive allosteric modulator of MGLUR5 |
RU2542100C1 (en) * | 2013-12-24 | 2015-02-20 | Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) | Co-crystalline form of theophylline with diflunisal or diclofenac |
TWI713497B (en) | 2015-02-26 | 2020-12-21 | 南韓商愛思開生物製藥股份有限公司 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same |
CN114450274A (en) | 2019-07-11 | 2022-05-06 | 伊斯凯普生物公司 | Indazoles and azaindazoles as LRRK2 inhibitors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR208397A1 (en) * | 1973-02-20 | 1976-12-27 | Ciba Geigy Ag | PROCEDURE FOR THE PREPARATION OF 1-PYRIDYLOXY-2-HYDROXY-3-AMINO-PROPANO1-PIRAZINYLOXY-2-HYDROXY-3-AMINO-PROPANE AND 1-PYRIMIDINYLOXY-2-HYDROXY-3-AMINO-PROPAN COMPOUNDS |
JP2689093B2 (en) * | 1986-01-30 | 1997-12-10 | 石原産業株式会社 | Substituted pyridine sulfonamide compounds, herbicides containing them and method for producing these compounds |
JP2000212076A (en) * | 1998-11-20 | 2000-08-02 | Takeda Chem Ind Ltd | Beta-amyloid protein production/secretion inhibitor |
US6586475B1 (en) * | 1998-11-20 | 2003-07-01 | Takeda Chemical Industries, Ltd. | β-amyloid protein production/secretion inhibitors |
AU2002214583A1 (en) * | 2000-10-11 | 2002-04-22 | Purdue Research Foundation | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof |
JP2002322163A (en) * | 2001-04-20 | 2002-11-08 | Sumitomo Pharmaceut Co Ltd | Piperazine derivative |
US6667327B2 (en) * | 2002-02-04 | 2003-12-23 | Hoffmann-La Roche Inc. | Pyridine amido derivatives |
US20040072802A1 (en) * | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
WO2004078719A1 (en) * | 2003-03-06 | 2004-09-16 | Ono Pharmaceutical Co., Ltd. | Indole derivative compounds and drugs containing the compounds as the active ingredient |
GB0418267D0 (en) * | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
WO2006106054A1 (en) * | 2005-04-06 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
US8138209B2 (en) * | 2005-07-13 | 2012-03-20 | Jenrin Discovery, Inc. | Substituted picolinamides as MAO-B inhibitors useful for treating obesity |
CN101321731A (en) * | 2005-12-20 | 2008-12-10 | 诺瓦提斯公司 | Nicotinic acid derivatives as modulators of metabotropic glutamate receptors |
US20090005363A1 (en) * | 2005-12-20 | 2009-01-01 | Ralf Glatthar | Organic Compounds |
US20110172230A1 (en) * | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
MX2009002684A (en) * | 2006-09-11 | 2009-06-05 | Novartis Ag | New uses of metabotropic glutamate receptors. |
WO2008038841A1 (en) * | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Thiadiazolone derivative and use thereof |
TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
US8853392B2 (en) * | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
WO2009067401A1 (en) * | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor |
ES2531023T3 (en) * | 2007-12-04 | 2015-03-09 | Hoffmann La Roche | Isoxazole-Pyridine Derivatives |
US7897621B2 (en) * | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
US8748623B2 (en) * | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
CN102414203B (en) * | 2009-05-07 | 2014-11-26 | 弗·哈夫曼-拉罗切有限公司 | Isoxazole-pyridine derivatives as GABA modulators |
-
2010
- 2010-09-21 EP EP10818037.3A patent/EP2482657A4/en not_active Withdrawn
- 2010-09-21 JP JP2012530978A patent/JP2013505297A/en active Pending
- 2010-09-21 BR BR112012006330A patent/BR112012006330A2/en not_active IP Right Cessation
- 2010-09-21 CN CN2010800523979A patent/CN102638979A/en active Pending
- 2010-09-21 RU RU2012116124/13A patent/RU2012116124A/en not_active Application Discontinuation
- 2010-09-21 US US12/886,950 patent/US20110183980A1/en not_active Abandoned
- 2010-09-21 MX MX2012003394A patent/MX2012003394A/en not_active Application Discontinuation
- 2010-09-21 WO PCT/US2010/049697 patent/WO2011035324A1/en active Application Filing
- 2010-09-21 IN IN3322DEN2012 patent/IN2012DN03322A/en unknown
- 2010-09-21 AU AU2010295288A patent/AU2010295288A1/en not_active Abandoned
- 2010-09-21 CA CA2774981A patent/CA2774981A1/en not_active Abandoned
-
2012
- 2012-03-21 IL IL218772A patent/IL218772A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL218772A0 (en) | 2012-06-28 |
RU2012116124A (en) | 2013-10-27 |
CN102638979A (en) | 2012-08-15 |
AU2010295288A1 (en) | 2012-05-03 |
JP2013505297A (en) | 2013-02-14 |
EP2482657A1 (en) | 2012-08-08 |
EP2482657A4 (en) | 2013-05-15 |
BR112012006330A2 (en) | 2017-07-04 |
CA2774981A1 (en) | 2011-03-24 |
IN2012DN03322A (en) | 2015-10-23 |
WO2011035324A1 (en) | 2011-03-24 |
US20110183980A1 (en) | 2011-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012013031A (en) | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. | |
MX2009013169A (en) | Benzamide mglur5 positive allosteric modulators and methods of making and using same. | |
MX2012004771A (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. | |
MX2011005242A (en) | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors. | |
SG178999A1 (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
MX2009012749A (en) | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor). | |
WO2012118563A3 (en) | 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same | |
MY153912A (en) | 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors | |
JO2907B1 (en) | 1,2,4TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
MX2012001552A (en) | Metabotropic glutamate receptor modulators. | |
TN2012000400A1 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
MX2010008714A (en) | Amide derivatives as positive allosteric modulators and methods of use thereof. | |
MX2009005461A (en) | N-oxides of 4,5-epoxy-morphinanium analogs. | |
EA201190302A1 (en) | 7-aryl-1,2,4-triazole [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | |
MY160490A (en) | Arylethynyl derivatives | |
IL189987A0 (en) | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists | |
MX2016010056A (en) | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof. | |
MX2009005252A (en) | Aminopyrrolidines as chemokine receptor antagonists. | |
MX2009005462A (en) | 7,8-saturated-4,5-epoxy-morphinanium analogs. | |
WO2009145996A3 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
WO2011057208A3 (en) | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
MX353209B (en) | D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE. | |
WO2013170072A3 (en) | Compounds for the treatment of neurological disorders | |
EP2575461A4 (en) | Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators | |
MX2012003394A (en) | O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |